Fund moves
37 tracked managers disclosed the same change for Q4 2025. From a 13F filed Feb 6, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Jan 7, 2026 · Filed Jan 8, 2026
Incyte's Head of US Oncology sold $1.18M of Incyte shares. The filing references vesting of compensation awards.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$1,184,064
Shares × reported transaction price
71 days after results of Oct 28, 2025, 34 days before results of Feb 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $110.57 on Jan 7, 2026, at its 52-week high, after an 8% rise over the previous 30 trading days
52-week range $55.17 (Apr 10, 2025) to $110.57 (Jan 7, 2026), 100% of the way up, from 250 adjusted closes. 30 trading days earlier: $102.06 on Nov 21, 2025. Describes the past only, not a forecast
RSI 72, 38% above its 200-day average, 10% above its 50-day average, at the 52-week high, 20-day volatility 34% a year, against the S&P 500: +7 points over 1 month, +24 points over 3 months, +50 points over 6 months
From the adjusted closes up to Jan 7, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
FDA approved Zynyz on Dec 17, 2025, 21 days before this trade.
New use approved (efficacy supplement). Active ingredient: Retifanlimab-Dlwr. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −0.6% | −0.3% | −0.3% |
| 30 days | +2.0% | 0.0% | +2.0% |
| 90 days | −9.3% | −2.0% | −7.2% |
| 180 days | +9.7% | +7.4% | +2.3% |
Past results only. Not a forecast.
Fund moves
37 tracked managers disclosed the same change for Q4 2025. From a 13F filed Feb 6, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
29 tracked managers disclosed the same change for Q4 2025. From a 13F filed Feb 5, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Insider filing
Traded Feb 2 · filed 2 days later
Routine share withholding; mechanical by default.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.